A photo of Michael Grimley.

Michael S. Grimley, MD


  • Medical Director, Division of Bone Marrow Transplantation and Immune Deficiency
  • Professor, UC Department of Pediatrics
I believe that each patient is unique. I use a cooperative approach to treatment, in which I partner with the treatment team, the patient and their family.
Michael S. Grimley, MD

About

Biography

I’ve been interested in medicine for as long as I can remember. My medical school experiences with the children solidified my feeling that pediatrics was the area I related to best.

Similarly, my exposure to pediatric and adult hematology/oncology patients and physicians in medical school confirmed that I wanted to work with these patients and colleagues.

As a bone marrow transplant physician, I believe that each patient is unique. I use a cooperative approach to treatment, in which I partner with the treatment team, the patient and their family.

My research involves finding treatments for and prevention of viral infections in immunocompromised patients.

When I’m not treating patients or involved in research, I enjoy spending time with my family.

MD: Emory University School of Medicine, Atlanta, GA, 1992.

Residency: Wilford Hall Medical Center, Lackland, AFB, TX, 1995.

Fellowship: Cincinnati Children’s Hospital Medical Center, 1999.

Certification: General Pediatrics, Pediatric Hematology/Oncology.

Licenses: Ohio, Texas.

Interests

Bone marrow transplantation for primary immunodeficiencies; cord blood transplants; leukemia

Services and Specialties

Cancer and Blood Diseases, Bone Marrow Transplantation BMT, Immune Deficiencies and Histiocytosis, Rare Lung Diseases

Research Areas

Bone Marrow Transplantation and Immune Deficiency, Cancer and Blood Diseases

Insurance Information

Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.

View Insurance Information

Publications

Overlap chronic GVHD is associated with adverse survival outcomes compared to classic chronic GVHD. Gorfinkel, L; Raghunandan, S; Watkins, B; Hebert, K; Neuberg, DS; Bratrude, B; Betz, K; Yu, A; Choi, SW; Davis, J; Horan, JT; Langston, A; Kean, LS; Qayed, M. Bone Marrow Transplantation. 2024; 59:680-687.

Immunophenotypic predictors of influenza vaccine immunogenicity in pediatric hematopoietic cell transplant recipients. Amarin, JZ; Dulek, DE; Simmons, J; Hayek, H; Chappell, JD; Nochowicz, CH; Kitko, CL; Schuster, JE; Muñoz, FM; Bocchini, CE; Englund, JA; Halasa, NB; Spieker, AJ; Kalams, SA. Blood Advances. 2024; 8:1880-1892.

Dabrafenib and trametinib in Langerhans cell histiocytosis and other histiocytic disorders. Cournoyer, E; Ferrell, J; Sharp, S; Ray, A; Jordan, M; Dandoy, C; Grimley, M; Roy, S; Lorsbach, R; Merrow, AC; Nelson, A; Bartlett, A; Picarsic, J; Kumar, A. Haematologica: the hematology journal. 2024; 109:1137-1148.

Use of Teduglutide in the Management of Gastrointestinal Graft-versus-Host Disease in Children and Young Adults. Ramos, KN; Leino, D; Luebbering, N; Grimley, MS; Badia, P; Davies, SM; Khandelwal, P. Transplantation and Cellular Therapy. 2024; 30:454.e1-454.e6.

Virus-Specific T Cells for the Treatment of Systemic Infections Following Allogeneic Hematopoietic Cell and Solid Organ Transplantation. Green, A; Rubinstein, JD; Grimley, M; Pfeiffer, T. Journal of the Pediatric Infectious Diseases Society. 2024; 13:S49-S57.

Preliminary Results of a Phase 2a Clinical Trial to Evaluate Safety, Tolerability and Antiviral Activity of Intravenous Brincidofovir (BCV IV) in Immunocompromised Patients with Adenovirus Infection. Grimley, M; Marón, GM; Gomez, CA; Prasad, VK; Dara, J; Lion, T; Papanicolaou, GA; Fukushima, K; Wynn, RF; Boeckh, MJ. Transplantation and Cellular Therapy. 2024; 30:s89.

Successful Use of Teduglutide As Adjunctive Therapy in the Management of GI GvHD in Children and Young Adults: A Single Center Case Series. Ramos, KN; Leino, D; Luebbering, N; Grimley, M; Badia, P; Davies, SM; Khandelwal, P. Transplantation and Cellular Therapy. 2024; 30:s136.

The Durability of Antibody Responses of Two Doses of High-Dose Relative to Two Doses of Standard-Dose Inactivated Influenza Vaccine in Pediatric Hematopoietic Cell Transplant Recipients: A Multi-Center Randomized Controlled Trial. Schuster, JE; Hamdan, L; Dulek, DE; Kitko, CL; Batarseh, E; Haddadin, Z; Stewart, LS; Stahl, A; Potter, M; Rahman, H; Munoz, FM; Danziger-Isakov, L; Spieker, AJ; Halasa, NB. Clinical Infectious Diseases. 2024; 78:217-226.

Viral specific T cell therapy in kidney transplant recipients - A single-center experience. Anand, M; Nysather, J; McGraw, G; Apewokin, S; Khoury, R; Grimley, MS; Bumb, S; Govil, A. Transplant Infectious Disease. 2023; 25:e14179.

Immunogenicity and Safety of Alternative Influenza Vaccination Strategies in Repeated Seasons in Pediatric Hematopoietic-Cell Transplant Recipients. Bahakel, H; Spieker, AJ; Stahl, A; Rahman, H; Amarin, J; Hamdan, L; Dulek, DE; Kitko, CL; Batarseh, E; Haddadin, Z; Englund, JA; Munoz, FM; Danziger-Isakov, L; Halasa, N. Journal of the Pediatric Infectious Diseases Society. 2023; 12:s21.

Patient Ratings and Comments

All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey

4.6
Overall Patient Rating